Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teduglutide in Infants 4 to 12 Months with SBS
NCT03571516Phase 3Completed
- Sponsor
- Takeda
- Start
- Aug 2018
- Primary completion
- Sep 2020
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 4
01
Overview
Phase 3, randomised, open-label trial in short bowel syndrome (SBS) comparing Teduglutide with Standard of Care (2 arms). Primary endpoint: Number of Participants Who Achieved At Least 20 Percent Reduction From Baseline in Weight-normalized Parenteral Support Volume at 24 weeks. Started Aug 2018; status: completed.
02
Drugs
teduglutide
03
Conditions
short bowel syndrome (SBS)
Beyond the preview
Go deeper on NCT03571516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03571516.